SGLT-2 Therapy Center

An SGLT-2 inhibitor reduces liver fat and ALT levels in people who have type 2 diabetes.

Man, 67 years of age, had been on GLP-1, SGLT-2, and metformin for over 4 years without difficulty or reported untoward side effects. He started taking the SGLT-2 before most health care professionals knew about the risk of DKA in people who have type 2 diabetes when taking SGLT-2s.

Adding an SGLT2 inhibitor to insulin therapy for patients with type 2 diabetes who'd required large doses of insulin helped them reduce their insulin dose.

Investigators analyze CVD-REAL study to determine impact of drug class on patients with T2D and HF history.

Key ADA poster summaries include liraglutide in type 1 diabetes, oral semaglutide, bottled water's association with type 2 diabetes, & SGLT-2 combo LIK066.

With over 6 million possible combinations, it is difficult to come up with the best treatment for each patient. The phase III DURATION-8 trial may help you to decide.

DEPICT-2 study of more than 800 people worldwide indicates positive results without added risk of severe hypoglycemia, but slight increase in DKA events.

One-year results of North American inTandem1 study show decreased HbA1c levels and lower risk of severe hypoglycemia.

The different mechanisms of action of these two drugs make them an excellent combination in the treatment of patients with type 2 diabetes mellitus (T2DM).

Sotagliflozin to be reviewed by the FDA as possible oral adjunct for people with insulin-treated type 1 diabetes.